Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (Nordic Exchange: BINV) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.

Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of receipt of such clearance), Roche will pay ThromboGenics and BioInvent an upfront payment of EUR50 million. In addition, ThromboGenics and BioInvent could potentially receive up to EUR450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. ThromboGenics and BioInvent will retain co-promotion rights for the product in the Benelux, Baltic and Nordic regions.

ThromboGenics and BioInvent are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers. Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by ThromboGenics and BioInvent. ThromboGenics and BioInvent in conjunction with Roche will form a Joint Steering Committee to oversee research and development activities. In addition, Roche will also provide funding to ThromboGenics and BioInvent for research on non-cancer indications an
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... This release is available in German . ... from the physics department at the TUM discovered an entirely ... grid of magnetic eddies. Together with the team of Professor ... properties of these eddies, so-called skyrmions, named after the British ...
... Calif., Feb. 21, 2012 Onyx Pharmaceuticals, Inc. (Nasdaq: ... conferences in February and March. 2012 Citi Global ... Healthcare Conference on Monday, February 27, 2012 at 10:00 a.m. Eastern ... Company 32nd Annual Health Care Conference Onyx will present at ...
... 21, 2012  Wake Forest Baptist Medical Center has ... a new state-of-the-art, world-class 242,000 square foot biotechnology ... growth of Wake Forest Baptist,s many renowned research ... companies generated by researchers, discoveries and space for ...
Cached Biology Technology:Saving data in vortex structures 2Onyx Pharmaceuticals to Present at Upcoming Investor Conferences 2Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salem's Growing Piedmont Triad Research Park 2Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salem's Growing Piedmont Triad Research Park 3Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salem's Growing Piedmont Triad Research Park 4
(Date:4/23/2014)... domestic heating may contribute to early fetal death according ... Research Institute of Children,s Hospital Los Angeles and Ulaanbaatar, ... , In a paper published today in the journal ... strong statistical correlations" between seasonal ambient air pollutants and ... has one of the highest levels of air pollution ...
(Date:4/23/2014)... hungry diner ripping open a dinner roll, a fuel ... open a hydrogen molecule. Now researchers have captured a ... halves of its hydrogen feast. The view confirms previous ... catalyst work better for alternative energy uses. , This ... where the hydrogen halves end up in the structure ...
(Date:4/23/2014)... shows that male black widow spiders prefer their female ... of mate preference by male spiders. , ... Maydianne Andrade, a professor in UTSC,s Department of Biological ... wild that males overwhelmingly chose to mate with well-fed, ... tell whether a potential mate is well-fed and unmated ...
Breaking Biology News(10 mins):Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Picky male black widow spiders prefer well-fed virgins 2
... research team has tested the utility of the short version ... disability in patients with depression, "which in the case of ... of the instrument." In Spain, more than 10% of ... is usually the first to screen an individual who feels ...
... today by ESA,s Envisat satellite, shows the vast cloud of ... Iceland, more than 1000 km away. Carried by winds ... the eruption of the Eyjafjallajoekull glacier in southwest Iceland has ... Scandinavia, with further disruption in northern Europe expected later today. ...
... This press release is available in French . ... of the 20th century, but new research shows initiatives of ... dollars as people might think. McGill University Biologist Dr. Jonathan ... most affected by them is a far more effective and ...
Cached Biology News:It takes only 5 minutes to assess disability in patients with depression 2Trying to eradicate a disease is a waste of money: researcher 2